DCM
DSGN icon

Driehaus Capital Management’s Design Therapeutics DSGN Stock Holding History

Driehaus Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.5M Buy
2,661,115
+916,128
+53% +$11.4M 0.22% 143
2026
Q1 		$18.6M Buy
1,744,987
+565,170
+48% +$5.72M 0.14% 212
2025
Q4 		$11.1M Buy
1,179,817
+103,581
+10% +$811K 0.08% 270
2025
Q3 		$8.1M Hold
1,076,236
– – 0.06% 294
2025
Q2 		$3.63M Buy
1,076,236
+162,837
+18% +$609K 0.03% 314
2025
Q1 		$3.53M Buy
913,399
+137,317
+18% +$655K 0.03% 310
2024
Q4 		$4.79M Buy
+776,082
New +$4.49M 0.04% 297

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return

Driehaus Capital Management's DSGN Position: Q2 2026 in Review

Driehaus Capital Management increased its Design Therapeutics (DSGN) stake by 53% in Q2 2026, buying an estimated $11.4M and bringing the position to 2,661,115 shares worth $38.5M. The position accounts for 0.22% of the portfolio, ranked #143.

Driehaus Capital Management first reported a position in DSGN in Q4 2024 and has held it in 7 quarters since. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Driehaus Capital Management held 2,661,115 shares of Design Therapeutics worth $38.5M as of Q2 2026.
  • Driehaus Capital Management bought 916,128 Design Therapeutics shares in Q2 2026, an estimated $11.4M.
  • Design Therapeutics made up 0.22% of Driehaus Capital Management's portfolio in Q2 2026, its #143 holding.
  • Driehaus Capital Management first reported a position in Design Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.